A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Intravenous and Subcutaneous RO7105705 Administered in Healthy Volunteers and Patients With Mild-to-Moderate Alzheimer's Disease

Trial Profile

A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Intravenous and Subcutaneous RO7105705 Administered in Healthy Volunteers and Patients With Mild-to-Moderate Alzheimer's Disease

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs RG 6100 (Primary) ; RG 6100 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 20 Jul 2017 Trial design presented at the Alzheimer's Association International Conference 2017.
    • 19 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 22 May 2017 Planned End Date changed from 2 May 2017 to 26 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top